JP5042447B2 - Mixed preparation - Google Patents

Mixed preparation Download PDF

Info

Publication number
JP5042447B2
JP5042447B2 JP2004165439A JP2004165439A JP5042447B2 JP 5042447 B2 JP5042447 B2 JP 5042447B2 JP 2004165439 A JP2004165439 A JP 2004165439A JP 2004165439 A JP2004165439 A JP 2004165439A JP 5042447 B2 JP5042447 B2 JP 5042447B2
Authority
JP
Japan
Prior art keywords
talc
coating
mixed preparation
substance
granular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2004165439A
Other languages
Japanese (ja)
Other versions
JP2004277431A (en
Inventor
博秋 中上
忠直 山尾
有生 鮒田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Priority to JP2004165439A priority Critical patent/JP5042447B2/en
Publication of JP2004277431A publication Critical patent/JP2004277431A/en
Application granted granted Critical
Publication of JP5042447B2 publication Critical patent/JP5042447B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

本発明は湿熱条件下でも固結せず、且つレボフロキサシンの不快な味もマスク可能な粒状製剤に関する。   The present invention relates to a granular preparation which does not solidify even under wet heat conditions and can mask the unpleasant taste of levofloxacin.

医薬品において錠剤やカプセル剤など種々の剤形が知られているが顆粒剤あるいは細粒剤などの粒状製剤の果たす役割は大きい。すなわち、投薬の際、投与量を自由に変えることができることに加え、特に小児や老人の服用性及びコンプラィアンスの向上において極めて重要である。そして、近年患者の高齢化が急速に進む中でその需要は増加している。
一方、粒状製剤であっても不快な味を有する薬物が含まれる場合においては必ずしも服用しやすい製剤とはなり得ない。これらの問題点を解決するため種々の製剤学的工夫がなされている。一般に最も多く用いられる製剤手法としてワックスや水不溶性高分子など口中で溶解しないコーティング剤を粒状物表面にコーティングする方法がある。この場合、従来はコーティング剤を有機溶媒に溶解させてスプレーコーティングを施す方法が用いられてきた。しかしながら有機溶媒を使用することは作業者への衛生上の悪影響、環境汚染及び製剤中への残留など問題点が多い。このため最近ではコーティング剤を可塑剤と共に水に分散させてコーティングを施す方法が見いだされ広く用いられるようになった。しかし、この方法もまた水に不安定な物質には不適当であり、更に水易溶性の薬物に適用した場合、薬物がコーティング液に溶けやすいため、コーティング時の粒状物同士の付着による凝集物の発生や被膜形成不良等の欠点を有する。またスプレーコーティングの場合、コーティング速度や温度等、製造条件の変動要因が多いため常に一定品質の製剤を得るための精度の高い条件管理が必要となる。
Various dosage forms such as tablets and capsules are known in medicine, but the role played by granular preparations such as granules or fine granules is great. That is, in addition to being able to freely change the dosage at the time of medication, it is extremely important for improving the dosage and compliance of children and the elderly. In recent years, the demand is increasing as the patient ages rapidly.
On the other hand, even in the case of a granular preparation, in the case where a drug having an unpleasant taste is included, it cannot necessarily be a preparation that is easy to take. Various pharmaceutical approaches have been made to solve these problems. In general, there is a method of coating the surface of a granular material with a coating agent that does not dissolve in the mouth, such as wax and a water-insoluble polymer, as the most commonly used preparation technique. In this case, conventionally, a method of spray coating by dissolving a coating agent in an organic solvent has been used. However, the use of an organic solvent has many problems such as sanitary adverse effects on workers, environmental pollution, and residual in the preparation. For this reason, recently, a method of coating by dispersing a coating agent in water together with a plasticizer has been found and widely used. However, this method is also unsuitable for substances that are unstable to water, and when applied to a readily water-soluble drug, the drug easily dissolves in the coating solution. And defects such as film formation failure. In the case of spray coating, there are many factors that cause fluctuations in manufacturing conditions such as coating speed and temperature, so it is necessary to always manage the conditions with high accuracy in order to obtain a preparation with a constant quality.

これとは別に苦味のマスキングを目的として油性物質であるモノステアリン酸グリセリンエステルを低融点物質として使用し、これを微粉状薬物とあるいは微粉状の賦形剤及び薬物と溶融造粒を行い、得られた粒状物をタルクのみをコーティング剤として溶融コーティングを行う方法があるが、該製法によって得られた粒状物は湿熱条件化に暴露させると経時的に固結する傾向があることがわかった。
一般に、油性物質を含有する造粒品を油性物質の融点以下の温度下に保存すると固結することが知られており(非特許文献1)、このような粒状物の固結に及ぼす造粒品の物性として造粒品の粒子径、油性物質含有量などが報告されている。このような粒状製剤の凝集抑制法及び固結の防止法として微粉添加剤の少量添加が報告されているが〔非特許文献2〜4〕、逆に、油性物質含有造粒品の系においてはこの微粉添加剤の少量添加は流動性を低下させ、固結を増大させるという特異的現象が報告されている(非特許文献1)。
Separately, for the purpose of masking bitterness, glyceryl monostearate, an oily substance, is used as a low-melting substance, and this is obtained by melt granulation with a pulverized drug or a pulverized excipient and drug. There is a method in which the obtained granular material is melt-coated using only talc as a coating agent, but it has been found that the granular material obtained by the production method tends to solidify over time when exposed to wet heat conditions.
In general, it is known that a granulated product containing an oily substance consolidates when stored at a temperature below the melting point of the oily substance (Non-patent Document 1), and granulation affects the consolidation of such a granular material. As the physical properties of the product, the particle size of the granulated product, the content of oily substances, etc. are reported. Although a small amount of fine powder additive has been reported as a method for suppressing aggregation and preventing caking of such granular preparations [Non-Patent Documents 2 to 4], conversely, in the system of granulated products containing oily substances It has been reported that the addition of a small amount of the fine powder additive reduces fluidity and increases caking (Non-Patent Document 1).

脇山尚樹、ファーム テック ジャパン(Pharm Tech Japan.), (1994),vol.10. p819)Naoki Wakiyama, Pharm Tech Japan. (1994), vol.10. P819) P.ヨーク、ジャーナル オブ ファーマシューティカル サイエンス(P. York. J. Pharm. Sci.), (1975),64, 1216-1221P. York, Journal of Pharmaceutical Sciences (P. York. J. Pharm. Sci.), (1975), 64, 1216-1221 S.ダウッドバーイ及びC.T.ローデス、ドラッグ デベロップメント アンド インダストリアル ファーマシー(S. Dawoodbhai and C. T. Rhodes, Drug Dev. Ind. Pham.), (1990), 16, 2409-2429S. Dawood Bai and C.I. T.A. Rhodes, Drug Development and Industrial Pharmacy (S. Dawoodbhai and C. T. Rhodes, Drug Dev. Ind. Pham.), (1990), 16, 2409-2429 G.ゴールドら(G. Gold et al.) J. Pharm. Sci., (1968), 57, 667-671G. Gold et al. J. Pharm. Sci., (1968), 57, 667-671

本発明は、湿熱条件下でも固結せず、かつレボフロキサシンの苦みも効果的にマスク可能な粒状製剤を提供することを目的とする。   An object of the present invention is to provide a granular preparation that does not solidify even under wet heat conditions and can effectively mask the bitterness of levofloxacin.

本発明は微粉状の油性低融点物質とレボフロキサシン、所望により賦形剤とを溶融造粒により造粒した粒状物に微粉状のエチルセルロースを溶融コーティングによりコーティングした粒状製剤及びその製造法に関する。   TECHNICAL FIELD The present invention relates to a granular preparation obtained by coating finely divided oily low-melting substance, levofloxacin, and optionally an excipient by melt granulation with finely divided ethylcellulose by melt coating, and a method for producing the same.

本発明の粒状製剤は優れた固結の防止効果のみならず、口中における味のマスキング、レボフロキサシンの溶出、外観、強度、安定性等の点でも優れた性質を有する。またその他にも以下の如き極めて有用な点を有する。
(1)一般のマスキング粒状物の製造と比較して結合液やコーティング液を調製する必要がない上に製造時間が大幅に短縮でき、また複雑な条件設定を必要とせず簡単な装置によって一定な品質の製品を収率良く製造できる。
(2)溶媒を使用しないため安全面、衛生面、公害面、製品中への残留等の危険性がなく更にレボフロキサシンの安定性も損なうことがない。
(3)油性低融点物質の粒度を変えることにより容易に製品の粒度をコントロールすることができる。例えば造粒時150〜250μmのモノステアリン酸グリセリンを使用すると粒子径250〜500μmの細粒剤が得られ、300〜850μmのモノステアリン酸グリセリンを使用すると粒子径500〜1400μmの顆粒剤を得ることができる。
(4)油性低融点物質及び疎水性で吸油性の高分子化合物の量あるいは賦形剤の種類及び量を調節することによりマスキング性やレボフロキサシンの溶出性を自由にコントロールすることができる。
The granular preparation of the present invention has not only excellent caking prevention effects, but also excellent properties in terms of taste masking in the mouth, elution of levofloxacin, appearance, strength, stability and the like. In addition, it has the following extremely useful points.
(1) Compared with the production of general masking particulates, it is not necessary to prepare a binding solution or a coating solution, and the production time can be greatly reduced. Quality products can be produced with good yield.
(2) Since no solvent is used, there is no danger of safety, hygiene, pollution, residue in the product, etc., and the stability of levofloxacin is not impaired.
(3) The particle size of the product can be easily controlled by changing the particle size of the oily low melting point substance. For example, when glyceryl monostearate having a particle size of 150 to 250 μm is used during granulation, a fine granule having a particle size of 250 to 500 μm is obtained, and when glyceryl monostearate having a particle size of 300 to 850 μm is used, a granule having a particle size of 500 to 1400 μm is obtained. Can do.
(4) Masking property and elution property of levofloxacin can be freely controlled by adjusting the amount of the oily low-melting substance and the hydrophobic and oil-absorbing polymer compound or the kind and amount of the excipient.

本発明において使用される油性低融点物質としては、融点が30〜100℃、より好ましくは、50〜80℃の油性物質であればよく、その例としてはモノステアリン酸グリセリンエステル、アセチル化グリセリンモノステアレート、ソルビタンモノステアレート、パルミチン酸ヘキサデシル、ステアリン酸オクタデシル等のエステル類、カルナウバロウ、ミツロウなどのロウ類、パラフィン、マイクロクリスタリンワックス等の炭化水素類、硬化油、木ロウ、カカオ脂などの油脂類等を、好ましくはモノステアリン酸グリセリンエステルをあげることができる。   The oily low melting point substance used in the present invention may be an oily substance having a melting point of 30 to 100 ° C., more preferably 50 to 80 ° C. Examples thereof include monostearic glycerin ester and acetylated glycerin mono. Stearate, sorbitan monostearate, esters such as hexadecyl palmitate and octadecyl stearate, waxes such as carnauba wax and beeswax, hydrocarbons such as paraffin and microcrystalline wax, oils and fats such as hardened oil, wood wax and cocoa butter Examples thereof include preferably monostearic acid glycerin ester.

該油性低融点物質の粒子径としては、通常850〜100μmのものが好適に使用されるが、造粒目的、即ち、得られる粒状製剤の種類によりその粒子径は異なる。例えば、顆粒を目的とするならば粒子径850〜360μm、好ましくは700〜350μmのものを使用すればよく、又、細粒を目的とするならば250〜100μm、好ましくは200〜110μmのものを使用すればよい。
尚、参考例及び実施例以外の本明細書の記載において、「粒子径」という場合は、平均粒子径を意味する。
このような油性低融点物質の使用量は最終的に得られる粒状製剤1重量部において、通常0.01〜0.5重量部、好ましくは0.05〜0.3重量部使用すればよい。
As the particle size of the oily low-melting-point substance, those having a particle size of 850 to 100 μm are usually preferably used, but the particle size varies depending on the purpose of granulation, that is, the type of granular preparation obtained. For example, a particle having a particle size of 850 to 360 μm, preferably 700 to 350 μm may be used for the purpose of granules, and a particle having a particle size of 250 to 100 μm, preferably 200 to 110 μm for fine particles. Use it.
In addition, in description of this specification other than a reference example and an Example, the term "particle diameter" means an average particle diameter.
The amount of such an oily low-melting substance used is usually 0.01 to 0.5 parts by weight, preferably 0.05 to 0.3 parts by weight, based on 1 part by weight of the finally obtained granular preparation.

本発明において使用される薬物としては、特に制限はないが、一般的には本発明の性質及び目的上苦味を有する薬物が好適に使用され、その具体例としては、ネフィラセタム、レボフロキサシン、エカバピド等を挙げることができる。
このような薬物の粒子径については、通常50μm以下、好ましくは10〜数μmのものが使用され、その使用量は、最終的に得られる粒状製剤1重量部において通常0.01〜0.5重量部使用される。該薬物を前記油性低融点物質と溶融造粒により造粒する過程においては、所望によりトウモロコシデンプン、乳糖、タルク等の賦形剤を用いて造粒してもよく、これらの賦形剤の粒子径は通常50μm以下、又その使用量は適量を、一般的には得られる粒状製剤1重量部において0.02〜0.3重量部程度である。
The drug used in the present invention is not particularly limited, but generally a drug having a bitter taste for the purpose and purpose of the present invention is preferably used, and specific examples thereof include nefiracetam, levofloxacin, ecabapid and the like. Can be mentioned.
The particle size of such a drug is usually 50 μm or less, preferably 10 to several μm, and the amount used is usually 0.01 to 0.5 in 1 part by weight of the finally obtained granular preparation. Used by weight. In the process of granulating the drug by melt granulation with the oily low-melting substance, if desired, the drug may be granulated using excipients such as corn starch, lactose, talc, etc., and particles of these excipients The diameter is usually 50 μm or less, and the amount used is an appropriate amount, generally about 0.02 to 0.3 parts by weight per 1 part by weight of the obtained granular preparation.

本発明における溶融造粒とは、上記の如き油性低融点物質を中心核としてそのまわりに薬物や賦形剤の粉体を該低融点物質の熱により融解する時に生じる粘着性を利用して流動下均一に付着させ単核状の粒状物を製造する方法をいう(「粒子設計と製剤技術」130〜132頁、平成5年10月30日(株)薬業時報社発行)。該溶融造粒は次のようにして行なわれる。即ち、上記の如き微粉状の油性低融点物質とレボフロキサシン扮体並びに所望により上記の如き賦形剤とを混合し、得られる混合物を前記油性低融点物質の融点以上の温度に加熱しながら流動攪拌し、次いで冷却することによりレボフロキサシンや賦形剤を油性低融点物質のまわりに均一に付着させ、次いで融点以下に冷却することにより単核状の粒状物を製造することができる。
上記の如き溶融造粒における加熱温度は、一般的には油性低融点物質の融点よりも5〜45℃程度高い温度であり、又、造粒時間は、使用する原材料や製造スケールによっても異なるが、1〜10kg程度の製造スケールにおいては通常10〜30分間である。
The melt granulation in the present invention is a fluid that uses the adhesiveness generated when the low melting point substance is melted by the heat of the low melting point substance around the oily low melting point substance as described above. This refers to a method for producing a mononuclear granular material by uniformly adhering to the bottom (“Particle Design and Formulation Technology”, pages 130-132, published on October 30, 1993 by Yakuho Hokpo Co., Ltd.). The melt granulation is performed as follows. That is, a fine powdery oily low-melting substance as described above is mixed with levofloxacin housing and, if desired, the excipient as described above, and the resulting mixture is heated and stirred at a temperature higher than the melting point of the oily low-melting substance. Then, by cooling, levofloxacin and excipients are uniformly attached around the oily low-melting substance, and then the mononuclear granular material can be produced by cooling below the melting point.
The heating temperature in the melt granulation as described above is generally about 5 to 45 ° C. higher than the melting point of the oily low melting point substance, and the granulation time varies depending on the raw materials used and the production scale. In the production scale of about 1 to 10 kg, it is usually 10 to 30 minutes.

このようにして得られた粒状物に、微粉状の疎水性で且つ吸油性の高分子化合物としてエチルセルロースを選択し、所望によりタルク等の賦形剤の微粉を溶融コーティングによりコーティングすることにより目的の粒状製剤とすることができる。
ここで、該高分子化合物の疎水性とは、具体的には水よりも油になじむ性質を意味し、このような性質を持った物質は、水に溶けにくいが、油や無極性溶媒には溶けやすくなる。一方、吸油性とは、具体的には油を選択的に吸収、膨潤する性質を意味する。
上記のエチルセルロースの粒子径については、通常10μm以下のものが使用され、その使用量は最終的に得られる粒状製剤1重量部において、0.0001〜0.5重量部程度、好ましくは0.001〜0.1重量部である。
又、上記の溶融コーティングにおいて、所望により添加される賦形剤の粒子径は、通常50μm以下、又その使用量は適量、一般的には得られる粒状物1重量部において0.1〜0.5重量部程度である。
By selecting ethylcellulose as the fine powdery hydrophobic and oil-absorbing polymer compound, and then coating the fine powder of excipients such as talc by melt coating on the granular material thus obtained. It can be a granular preparation.
Here, the hydrophobicity of the polymer compound specifically means a property that is more compatible with oil than water, and a substance having such a property is hardly soluble in water, but is not suitable for oil or nonpolar solvents. Becomes easy to melt. On the other hand, the oil absorbing property specifically means the property of selectively absorbing and swelling oil.
The particle size of the above-mentioned ethyl cellulose is usually 10 μm or less, and the amount used is about 0.0001 to 0.5 parts by weight, preferably 0.001 in 1 part by weight of the finally obtained granular preparation. -0.1 parts by weight.
In the above melt coating, the particle diameter of the excipient added as desired is usually 50 μm or less, and the amount used is an appropriate amount, generally 0.1 to 0. About 5 parts by weight.

本発明における溶融コーティングとは、溶融造粒にて製した粒状物と微粉状のコーティング剤とを混合しこれを流動下油性低融点物質の融点以上に加熱して油性低融点物質を融解、粒状物の表面上に溶出させ、その付着力を利用してコーティング剤を粒状物のまわりに付着させて被覆層を形成させることをいう(「粒子設計と製剤技術」132〜134頁平成5年10月30日(株)薬業時報社発行)。
本発明においては、溶融コーティングは次のようにして行えばよい。即ち、上記の如き溶融造粒にて製した粒状物と微粉状のエチルセルロース及び所望により微粒状の賦形剤とを混合し、流動下、転動下、或いは攪拌下、使用した油性低融点物質の融点以上の温度で加熱して造粒することによりエチルセルロースを粒状物のまわりに付着させることができ、最終的に油性低融点物質及びエチルセルロース、所望により賦形剤からなる被覆層を形成させることができる。
該溶融コーティングにおける加熱条件及び造粒時間は溶融造粒のそれと同じで十分な効果を期待することができる。
溶融コーティング終了後、冷却すれば目的とする粒状製剤を得ることができる。
The melt coating in the present invention is a mixture of a granular material produced by melt granulation and a fine powder coating agent, and this is heated to a temperature higher than the melting point of the oily low melting point material under flow to melt the oily low melting point material, granular This refers to elution on the surface of a product, and a coating layer is formed by attaching a coating agent around the granular material using its adhesive force (“Particle Design and Formulation Technology”, pages 132-134, October 1993). May 30 (published by Yakuho Hokpo).
In the present invention, the melt coating may be performed as follows. That is, an oily low-melting-point substance used by mixing granular material produced by melt granulation as described above, finely divided ethyl cellulose and, if desired, finely granular excipient, under flow, rolling or stirring. By heating and granulating at a temperature equal to or higher than the melting point, ethyl cellulose can be adhered around the granular material, and finally a coating layer comprising an oily low melting point substance and ethyl cellulose, and optionally an excipient is formed. Can do.
The heating conditions and granulation time in the melt coating are the same as those of melt granulation, and a sufficient effect can be expected.
After completion of melt coating, the desired granular preparation can be obtained by cooling.

尚、本発明において使用される各種の粉体を製造するには、ボールミルやジェットミル等の通常の微粉砕法に従って微粉化し、これを、目的の孔径を有する篩を用いて篩過すればよい。
このようにして得られた粒状製剤は適当な孔径を有する篩を用いて篩過し、より均一な粒子径の粒状製剤とすることができる。
かくして得られる粒状製剤は、適当な流動化剤及び/又はコーティング剤と混合すれば、一層好ましい固結防止効果を期待することができる。流動化剤としては、タルク、軽質無水ケイ酸、メタケイ酸アルミン酸マグネシウム及びそれらの混合物等を、又、コーティング剤としては、酸化チタン、酸化マグネシウム及びそれらの混合物等をあげることができる。これら流動化剤及び/又はコーティング剤は、上記の如く混合して得られる最終粒状製剤の全量において、通常、1%〜5%程度使用される。該流動化剤又はコーティング剤の粒子径については、市販のものの粒子径を使用すれば十分であるが、通常、0.001〜75μm程の範囲から適宜選択すればよい。
In addition, in order to produce various powders used in the present invention, the powder may be pulverized according to a normal pulverization method such as a ball mill or a jet mill, and this may be sieved using a sieve having a target pore size. .
The granular preparation thus obtained can be sieved using a sieve having an appropriate pore size to obtain a granular preparation having a more uniform particle size.
If the granular preparation thus obtained is mixed with an appropriate fluidizing agent and / or coating agent, a more preferable anti-caking effect can be expected. Examples of the fluidizing agent include talc, light anhydrous silicic acid, magnesium aluminate metasilicate, and a mixture thereof. Examples of the coating agent include titanium oxide, magnesium oxide, and a mixture thereof. These fluidizing agents and / or coating agents are usually used in an amount of about 1% to 5% in the total amount of the final granular preparation obtained by mixing as described above. As for the particle size of the fluidizing agent or coating agent, it is sufficient to use a commercially available particle size, but usually it may be appropriately selected from the range of about 0.001 to 75 μm.

次に実施例をあげて本発明を具体的に説明する。
参考例1
流動層造粒機(グラットWSG−5型)にネフィラセタム(平均粒子径:50μm以下)1.2kg、タルク(粒子径:100μm以下)1.08kg、乳糖(粒子径:250μm以下)0.534kg、トウモロコシデンプン(粒子径:125μm以下)0.27kg、モノステアリン酸グリセリン(平均粒子径100〜200μm)0.846kgを入れ吸気温度90℃で加熱流動させながら造粒した後冷却し、500μmの篩にて篩過し、粒状物(細粒剤)を得た。この粒状物3.275kgをタルク(粒子径:前記と同じ)1.650kgとともに再び流動層造粒機に入れ、吸気温度90℃で加熱しながら流動させ、粉末がすべて被コーティング粒状物に付着(即ち、溶融コーティング)した後(約20分)、ダンパー操作により熱風を室内空気に変え試料温度を40℃まで冷却した粒状物(細粒剤)を得た。
Next, the present invention will be specifically described with reference to examples.
Reference example 1
In a fluid bed granulator (Glat WSG-5 type), 1.2 kg of nefiracetam (average particle size: 50 μm or less), talc (particle size: 100 μm or less) 1.08 kg, lactose (particle size: 250 μm or less) 0.534 kg, Corn starch (particle size: 125 μm or less) 0.27 kg, glyceryl monostearate (average particle size 100-200 μm) 0.846 kg, granulated while heating and flowing at an intake air temperature of 90 ° C., cooled, and passed through a 500 μm sieve And sieved to obtain a granular material (fine granule). 3.275 kg of this granular material is again put into a fluidized bed granulator together with 1.650 kg of talc (particle size: the same as above), and fluidized while heating at an intake air temperature of 90 ° C., and all the powder adheres to the coated granular material ( That is, after melt coating) (about 20 minutes), hot air was changed to room air by a damper operation to obtain a granular material (fine granule) in which the sample temperature was cooled to 40 ° C.

参考例2
参考例1で得た溶融コーティング前の粒状物にタルクの一部をエチルセルロース(平均粒子径:10μm以下)に代えてなるコーティング剤の該エチルセルロース量を2〜50重量%まで変化させて調製したものを用意し、参考例1と同様の方法で溶融コーティングして粒状物(細粒剤)を得た。
粒状物につき固結試験、口中マスキング試験及び溶出試験(T75%)を行った。固結試験は肉眼によって評価した(表1)。
表1中、+は固結を、±は一部固結を、−は固結なしを示す。
Reference example 2
What was prepared by changing the amount of ethyl cellulose of the coating agent obtained by replacing part of talc with ethyl cellulose (average particle size: 10 μm or less) to 2 to 50% by weight in the granular material before melt coating obtained in Reference Example 1 Was prepared and melt coated in the same manner as in Reference Example 1 to obtain a granular material (fine granule).
The granular material was subjected to a caking test, a mouth masking test, and a dissolution test (T75%). The consolidation test was evaluated by the naked eye (Table 1).
In Table 1, + indicates consolidation, ± indicates partial consolidation, and-indicates no consolidation.

Figure 0005042447
Figure 0005042447

表1から明らかなようにエチルセルロースを添加した場合には、その添加量の増加にかかわらず粒状製剤のブロッキングの防止効果が認められた。
口中マスキング試験は試料0.75gを口中に含み苦味を感じるまでの時間を測定し(N=6)、平均値を示した(かっこ内は最低値と最高値を示す)。溶出試験は日局一般試験法溶出試験法第2法により行い、水を使用して試験開始後、2、5、10、15、20、30、40、60分までの試験液をサンプリングし、ネフィラセタムの吸光度を測定し、その溶出率75%に達する時間(T75%)を計算により求めた(表2)。
As apparent from Table 1, when ethyl cellulose was added, the blocking effect of the granular preparation was recognized regardless of the increase in the amount added.
In the mouth masking test, 0.75 g of sample was included in the mouth and the time until bitterness was felt was measured (N = 6), and the average value was shown (the values in parentheses indicate the lowest and highest values). The dissolution test is carried out according to the Japanese Pharmacopoeia General Test Method Dissolution Test Method No. 2. After starting the test using water, sample the test solution up to 2, 5, 10, 15, 20, 30, 40, 60 minutes, The absorbance of nefiracetam was measured, and the time to reach 75% elution rate (T75%) was determined by calculation (Table 2).

Figure 0005042447
Figure 0005042447

表2に示すようにエチルセルロースの添加量を増加するとマスキング時間は徐々に増加する。一方、溶出時間(T75%)については添加量が10%までは無添加の試料と大きな変化はないが添加量が10%を越すと増加する傾向があった。   As shown in Table 2, the masking time gradually increases as the amount of ethyl cellulose added is increased. On the other hand, the elution time (T75%) was not significantly different from the non-added sample up to an addition amount of 10%, but tended to increase when the addition amount exceeded 10%.

参考例3
参考例2Aで得られた粒状製剤988gをタルク及び軽質無水ケイ酸の混合物(混合比9:1 w/w)12gとよく混合し、流動化剤混合製剤を得た。
Reference example 3
988 g of the granular preparation obtained in Reference Example 2A was mixed well with 12 g of a mixture of talc and light silicic anhydride (mixing ratio 9: 1 w / w) to obtain a fluidizing agent mixed preparation.

参考例4
流動層造粒機(FLO−5型)にレボフロキサシン(平均粒子径:20μm以下)0.6kg、タルク1.5kg、乳糖1.176kg、モノステアリン酸グリセリン(平均粒子径100〜200μm)0.924kgを入れ吸気温度90℃で加熱流動させながら造粒した後冷却し、500μmの篩にて篩過し、粒状物(細粒剤)を得た。この粒状物3.5kgをタルク1.5kgとともに再び流動層造粒機に入れ、吸気温度90℃で加熱しながら流動させ、粉末がすべて被コーティング粒状物に付着(溶融コーティング)した後(約15分)、ダンパー操作により熱風を室内空気に変え試料温度を40℃まで冷却した粒状物(細粒剤)を得た。尚、使用したタルク及び乳糖の粒子径は参考例1と同じにした。
Reference example 4
In a fluidized bed granulator (FLO-5 type), levofloxacin (average particle size: 20 μm or less) 0.6 kg, talc 1.5 kg, lactose 1.176 kg, glyceryl monostearate (average particle size 100 to 200 μm) 0.924 kg And granulated while heating and flowing at an intake air temperature of 90 ° C., cooled, and sieved with a 500 μm sieve to obtain a granular material (fine granule). After 3.5 kg of this granular material is again put into a fluidized bed granulator together with 1.5 kg of talc, it is fluidized while heating at an intake air temperature of 90 ° C., and after all the powder adheres to the coated granular material (melt coating) (about 15 Minute), the granular material (fine granule agent) which changed hot air into room air by damper operation, and cooled the sample temperature to 40 degreeC was obtained. The particle diameters of talc and lactose used were the same as in Reference Example 1.

実施例1
参考例4で得た溶融コーティング前の粒状物にタルクの一部をエチルセルロース(粒子径:10μm以下)に代えてなるコーティング剤の該エチルセルロース量を11.7重量%としたものを用意し、参考例4と同様の方法で溶融コーティングして粒状物(細粒剤)を得た。
得られた粒状物につき口中マスキング試験及び溶出試験(T75%)を行い、苦味を感じるまでの時間の最低値及び最高値を示し(表3)、又、溶出率75%に達する時間を示した(表3)。
Example 1
Prepare the granular material before melt coating obtained in Reference Example 4 with a coating agent obtained by replacing part of talc with ethyl cellulose (particle diameter: 10 μm or less) in which the amount of ethyl cellulose is 11.7% by weight. A granular material (fine granule) was obtained by melt coating in the same manner as in Example 4.
The resulting granular product was subjected to a mouth masking test and dissolution test (T75%), showing the minimum and maximum time until bitterness was felt (Table 3), and the time to reach a dissolution rate of 75%. (Table 3).

Figure 0005042447
Figure 0005042447

実施例2
実施例1で得られた粒状製剤967gを軽質無水ケィ酸及びタルク混合物(混合比;10:1 w/w、混合物の平均粒子径:50μm以下)33gと混合し、流動化剤混合製剤を得、びん詰めとした。
得られたびん詰め製剤につき以下の固結試験を行った。結果を表4に示した。
固結試験方法
試料20gを5号規格瓶に入れ、びん詰め製剤とし、任意の環境で静置保存する。保存後のびん詰め製剤を室温まで自然冷却(室温1時間以上)した後、びんを静かに回転させ、びんを逆さにする。このとき、試料がびん内に残留する場合を+(固結あり)、試料の残留はないが排出した試料に凝集物を認める場合を±(一部固結)、残留及び凝集物を認めない場合を、一(固結なし)とした。
Example 2
967 g of the granular preparation obtained in Example 1 is mixed with 33 g of a light caustic anhydride and talc mixture (mixing ratio: 10: 1 w / w, average particle diameter of the mixture: 50 μm or less) to obtain a fluidizing agent mixed preparation. , Bottled.
The following caking test was performed on the obtained bottled preparation. The results are shown in Table 4.
Consolidation test method Place 20 g of a sample into a No. 5 standard bottle to make a bottled preparation, and store it in an arbitrary environment. The bottled preparation after storage is naturally cooled to room temperature (room temperature for 1 hour or more), and then the bottle is gently rotated to invert the bottle. At this time, when the sample remains in the bottle + (consolidated), when there is no sample remaining but aggregates are observed in the discharged sample ± (partially consolidated), no residue and aggregates are recognized The case was defined as one (no consolidation).

Figure 0005042447
Figure 0005042447

実施例3
実施例1で得られた粒状製剤959.5gを酸化チタン及び軽質無水ケイ酸(混合比;20.5:20 w/w、混合物の平均粒子径:50μm以下)40.5gと混合し、流動化剤およびコーティング剤混合製剤を得、びん詰めとし、固結試験を行った。結果を表5に示した。
Example 3
959.5 g of the granular preparation obtained in Example 1 was mixed with 40.5 g of titanium oxide and light anhydrous silicic acid (mixing ratio; 20.5: 20 w / w, average particle diameter of the mixture: 50 μm or less), and flowed An agent and coating agent mixed preparation was obtained, bottled, and subjected to a caking test. The results are shown in Table 5.

Figure 0005042447
Figure 0005042447

参考例5
流動層造粒機(FLO−5型)にネフィラセタム(平均粒子径:50μm以下)1.2kg、タルク0.87kg、乳糖0.534kg、トウモロコシデンプン(粒子径:125μm以下)0.27kg、モノステアリン酸グリセリン(平均粒子径100〜200μm)0.846kg、クロスカルメロースナトリウム(粒子径:250μm以下)0.12kgを入れ吸気温度90℃で加熱流動させながら造粒した後冷却し、500μmの篩にて篩過し、粒状物(細粒剤)を得た。この粒状物3.2kgをタルク1.65kgおよびエチルセルロース(平均粒子径:10μm以下)0.035kgとともに再び流動層造粒機に入れ、吸気温度90℃で加熱しながら流動させ、粉末がすべて被コーティング粒状物に付着(即ち、溶融コーティング)した後(約20分)、ダンパー操作により熱風を室内空気に変え試料温度を40℃まで冷却した粒状物(細粒剤)を得た。この粒子物980gを酸化チタン及び軽質無水ケイ酸の混合物(混合比;15:5 w/w、混合物の平均粒子径:50μm以下)と混合し、流動化剤及びコーティング剤混合製剤を得、そのうち20gを5号規格瓶に入れ、びん詰め製剤とした。尚、使用したタルク及び乳糖の粒子径は参考例1と同じにした。
得られたびん詰め製剤につき固結試験を行った。結果を表6に示した。
Reference Example 5
Fluidized bed granulator (FLO-5 type) with nefilacetam (average particle size: 50 μm or less) 1.2 kg, talc 0.87 kg, lactose 0.534 kg, corn starch (particle size: 125 μm or less) 0.27 kg, monostearin Add 0.846 kg of glycerin acid (average particle size 100-200 μm) and 0.12 kg of croscarmellose sodium (particle size: 250 μm or less), granulate while heating and flowing at an intake air temperature of 90 ° C., cool, and put on a 500 μm sieve And sieved to obtain a granular material (fine granule). 3.2 kg of this granular material was put into a fluidized bed granulator together with 1.35 kg of talc and 0.035 kg of ethyl cellulose (average particle size: 10 μm or less) and fluidized while heating at an intake air temperature of 90 ° C., and all the powder was coated. After adhering to the granular material (that is, melt coating) (about 20 minutes), a hot air was changed to room air by a damper operation to obtain a granular material (fine particle agent) cooled to 40 ° C. 980 g of these particles are mixed with a mixture of titanium oxide and light anhydrous silicic acid (mixing ratio: 15: 5 w / w, average particle diameter of the mixture: 50 μm or less) to obtain a fluidizing agent and coating agent mixed preparation, 20 g was put into a No. 5 standard bottle to make a bottled preparation. The particle diameters of talc and lactose used were the same as in Reference Example 1.
The caking preparation obtained was subjected to a consolidation test. The results are shown in Table 6.

Figure 0005042447
Figure 0005042447

Claims (6)

微粉状の融点が30〜100℃の油性低融点物質とレボフロキサシンに、賦形剤を混合して溶融造粒により造粒した粒状物に、タルク及び微粉状のエチルセルロースを添加し、溶融コーティングによりコーティングした粒状製剤であって、前記油性低融点物質は、モノステアリン酸グリセリンエステル、アセチル化グリセリンモノステアレート、ソルビタンモノステアレート、パルミチン酸ヘキサデシル、及びステアリン酸オクタデシルから選択されるエステル類であり、前記賦形剤は、トウモロコシデンプン及び乳糖の少なくとも何れかと、タルクを含む賦形剤である、粒状製剤と、
タルク、軽質無水ケイ酸、メタケイ酸アルミン酸マグネシウム及びそれらの混合物から選択される流動化剤、及び/又は
酸化チタン、酸化マグネシウム及びそれらの混合物から選択されるコーティング剤
からなる混合製剤
Add talc and pulverized ethylcellulose to granulated material by mixing excipients with olefloxacin, an oily low-melting substance with a fine powder melting point of 30-100 ° C, and coating by melt coating The oily low-melting substance is an ester selected from glyceryl monostearate, acetylated glyceryl monostearate, sorbitan monostearate, hexadecyl palmitate, and octadecyl stearate, The excipient is a granular preparation that is an excipient containing at least one of corn starch and lactose and talc, and
A fluidizing agent selected from talc, light anhydrous silicic acid, magnesium aluminate metasilicate and mixtures thereof, and / or
Coating agent selected from titanium oxide, magnesium oxide and mixtures thereof
A mixed preparation consisting of
前記賦形剤は、乳糖およびタルクからなる請求項1に記載の混合製剤。 The mixed preparation according to claim 1, wherein the excipient comprises lactose and talc. 前記賦形剤が、トウモロコシデンプン、乳糖およびタルクからなる請求項1に記載の混合製剤。 The mixed preparation according to claim 1, wherein the excipient comprises corn starch, lactose and talc. 油性低融点物質がモノステアリン酸グリセリンエステルである請求項1〜3のいずれか1項に記載の混合製剤。 The mixed preparation according to any one of claims 1 to 3, wherein the oily low melting point substance is glyceryl monostearate. 油性低融点物質の粒子径が100〜850μmである請求項1〜4のいずれか1項に記載の混合製剤。 The mixed preparation according to any one of claims 1 to 4, wherein the oily low-melting-point substance has a particle size of 100 to 850 µm. エチルセルロースは、粒状製剤1重量部において、0.001〜0.1重量部である請求項1〜5のいずれか1項に記載の混合製剤。 Ethyl cellulose is 0.001-0.1 weight part in 1 weight part of granular preparations, The mixed preparation of any one of Claims 1-5.
JP2004165439A 1995-07-21 2004-06-03 Mixed preparation Expired - Lifetime JP5042447B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2004165439A JP5042447B2 (en) 1995-07-21 2004-06-03 Mixed preparation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP20672695 1995-07-21
JP1995206726 1995-07-21
JP2004165439A JP5042447B2 (en) 1995-07-21 2004-06-03 Mixed preparation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP1997506543 Division 1996-07-19

Publications (2)

Publication Number Publication Date
JP2004277431A JP2004277431A (en) 2004-10-07
JP5042447B2 true JP5042447B2 (en) 2012-10-03

Family

ID=33301340

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004165439A Expired - Lifetime JP5042447B2 (en) 1995-07-21 2004-06-03 Mixed preparation

Country Status (1)

Country Link
JP (1) JP5042447B2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006176461A (en) * 2004-12-24 2006-07-06 Dai Ichi Seiyaku Co Ltd Granulated material
US8524735B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
PT1901749T (en) * 2005-05-18 2016-11-04 Raptor Pharmaceuticals Inc Aerosolized fluoroquinolones and uses thereof
SI2001445T1 (en) * 2006-03-16 2015-02-27 Euro-Celtique S.A. Pharmaceutical spheroids
JP2012505222A (en) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド Inhalation of levofloxacin to reduce lung inflammation
PL2344129T3 (en) 2008-10-07 2018-07-31 Horizon Orphan Llc Aerosol fluoroquinolone formulations for improved pharmacokinetics
ES2739979T3 (en) 2009-09-04 2020-02-05 Horizon Orphan Llc Use of levofloxacin spray for the treatment of cystic fibrosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58214333A (en) * 1982-06-04 1983-12-13 Dai Ichi Seiyaku Co Ltd Granular substance
JPH0647531B2 (en) * 1986-02-06 1994-06-22 第一製薬株式会社 Method for manufacturing sustained-release granules
JP3130058B2 (en) * 1991-02-15 2001-01-31 第一製薬株式会社 Masked granules
JP2915590B2 (en) * 1991-02-15 1999-07-05 第一製薬株式会社 Masked granules
JP2538134B2 (en) * 1991-04-08 1996-09-25 田辺製薬株式会社 Sustained release preparation and method for producing the same
JPH04321621A (en) * 1991-04-18 1992-11-11 Tanabe Seiyaku Co Ltd Sustained release granular agent and preparation thereof
JP2892858B2 (en) * 1991-05-15 1999-05-17 田辺製薬株式会社 Controlled release formulation and method for producing the same

Also Published As

Publication number Publication date
JP2004277431A (en) 2004-10-07

Similar Documents

Publication Publication Date Title
WO1996019200A1 (en) Sustained-release granular preparation and process for producing the same
KR100417746B1 (en) Manufacturing method of granular preparation
JPH0778023B2 (en) Cefuroxime acetyl oral formulation
JP3349535B2 (en) Method for producing spherical granules
JP5173431B2 (en) Anhydrous lactose aggregates and their production
JP5042447B2 (en) Mixed preparation
WO1996041628A1 (en) Granules containing pranlukast, process for producing the granules, and method of lowering cohesiveness of pranlukast
JP3130058B2 (en) Masked granules
US4994458A (en) Process for rotary fluid bed granulation of riboflavin
JPH0959156A (en) Granulate containing pranlukast, its production and improvement in adhering aggregateion of pranlukast
JP2915590B2 (en) Masked granules
JP2006517929A (en) Method for producing agglomerates using melt agglomeration
US5236920A (en) Granulated riboflavin product having high flowability, high riboflavin content
HU221435B (en) Pellet-based pharmaceutical composition of controlled release with high content of potassium-chloride, and process for it's production
JP2000504309A (en) Pharmaceutical granules
JP2915653B2 (en) Masked granules
CN115154424B (en) Low-hygroscopicity solid dispersion containing sodium valproate, preparation method thereof and sustained-release tablet core
JPS62181214A (en) Sustained release granular material
CA2227443C (en) Granular preparation and producing process thereof
JP2008184393A (en) Improvement of water solubility of hardly water-soluble medicine by mix-grinding with acrylic copolymer, and preparation of sustained release type particle
JPS62153213A (en) Enteric granular agent
JP2001151671A (en) Particle preparation having protrusion
JP2004269506A (en) Sustained release type compounded unit preparation
JPH023608A (en) Slowly releasing ibuprofen preparation
WO2021084030A1 (en) Oral pharmaceutical composition comprising a melt-agglomerated active ingredient core

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040714

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20060425

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20071127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080625

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080825

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20080904

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080904

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091117

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100217

A911 Transfer of reconsideration by examiner before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100325

A912 Removal of reconsideration by examiner before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100903

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120210

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120514

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120711

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150720

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term